Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
idarucizumab
- Development stage
- Approved
- Lead developer
- Boehringer Ingelheim
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Idarucizumab is a humanized monoclonal antibody fragment (Fab) that serves as a specific reversal agent for the direct thrombin inhibitor dabigatran. It binds to dabigatran and its metabolites with an affinity approximately 350 times higher than that of thrombin, effectively neutralizing the anticoagulant effect without possessing intrinsic procoagulant or anticoagulant activity. Developed by Boehringer Ingelheim, it was the first specific reversal agent approved for a non-vitamin K antagonist oral anticoagulant (NOAC). It is primarily indicated for patients treated with dabigatran (Pradaxa) who require rapid reversal of anticoagulation due to life-threatening or uncontrolled bleeding, or before emergency surgery or urgent procedures.
- Brand names
- PraxbindPrizbind
- Other names
- idarucizumab
02
Targets
F2 (Thrombin)
Beyond the preview
Go deeper on idarucizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on idarucizumab.